News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

ProfoundBio Commences Phase 1/2 Clinical Trial for PRO1107: Targeting PTK7 with Unique Hydrophilic MMAE-Based Linker-Drug

Monday, February 05, 2024

ProfoundBio a biotechnology firm currently in the clinical stage has commenced dosing in the Phase clinical trial of PRO an innovative antibodydrug conjugate therapy for cancer ProfoundBio emphasized the significance of this milestone stating

Graviton Bioscience Secures Strategic Funding from Sanofi to Advance Development of Innovative ROCK2 Inhibitors

Friday, February 02, 2024

Graviton Bioscience a clinicalstage biotechnology firm focused on developing therapies that inhibit RhoRhoassociated coiledcoil containing protein kinase ROCK has recently secured a strategic investment from Sanofi

RS Oncology Initiates Phase 2 Trial (MITOPE) for RSO-021 in Malignant Pleural Mesothelioma and Lung Metastases

Friday, February 02, 2024

RS Oncology a clinicalstage biotechnology company focused on developing innovative therapies for mesothelioma and other diseases has successfully administered the first dose to a patient in the Phase dose expansion

AustinPx and Microsize Collaborate on KinetiSol® Technology

Thursday, February 01, 2024

AustinPx and Microsize two contract development and manufacturing organizations have formed a strategic partnership to expedite the commercial application of AustinPxs KinetiSol Technology platform Through this collaboration AustinPxs clients will be...

Ryvu Therapeutics Initiates Dosing for First Patient in Phase II Study (RIVER-81) Evaluating RVU120 in Combination with Venetoclax for Relapsed/Refractory AML Treatment

Thursday, February 01, 2024

Ryvu Therapeutics has recently initiated a Phase II clinical trial RIVER in collaboration with venetoclax for the treatment of patients with relapsedrefractory acute myeloid leukemia

Jaguar Gene Therapy Secures FDA IND Approval to Explore JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome

Thursday, February 01, 2024

Jaguar Gene Therapy a biotechnology firm specializing in advancing gene therapy for severe genetic diseases has received clearance from the US Food and Drug Administration for its Investigational New Drug

Collaborative Effort for Advanced Cancer Therapies: Qubit Pharma, Institut Curie, and University of Bordeaux

Wednesday, January 31, 2024

Qubit Pharmaceuticals a deeptech company specializing in drug discovery through AI and simulation accelerated by hybrid HPC and quantum computing is collaborating with Institut Curie Frances leading cancer research center

Singleron Unveils AccuraSCOPE® Single-Cell Transcriptome Technology

Wednesday, January 31, 2024

Singleron Biotechnologies a leading player in singlecell multiomic solutions for precision medicine has introduced two innovative products the AccuraSCOPE Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE Single Cell FullLength Tra...

Oxford Biomedica Successfully Concludes Acquisition of ABL Europe

Tuesday, January 30, 2024

Oxford Biomedica plc has successfully completed the acquisition of ABL Europe SAS from Institut Mrieux SA solidifying its standing as a leading cell and gene therapy Contract Development and Manufacturing Organization

Vergent Bioscience Reveals Phase 2 Findings Indicating VGT-309's Ability to Visualize Lung Tumors During Surgery

Monday, January 29, 2024

Vergent Bioscience recently shared new findings at the th Annual Meeting of The Society of Thoracic Surgeons The data reveal that VGT their investigational tumortargeted fluorescent imaging agent